CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


PTC299Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2837 hospitalized children with Covid19 Wiki 1.00
drug2163 SOC Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.06
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)

This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.

NCT04439071 Pneumonia COVID-19 Coronavirus Drug: PTC299 Other: SOC Drug: Placebo
MeSH:Coronavirus Infections Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Respiratory improvement is defined as sustained peripheral oxygen saturation (SpO2) ≥94% on room air.

Measure: Time from Randomization to Respiratory Improvement

Time: up to Day 28

Secondary Outcomes

Measure: Percentage of Participants Requiring Invasive Ventilation

Time: up to Day 28

Measure: Percentage of Participants Requiring Supplemental Oxygen or Non-Invasive Ventilation in Participants who did not Require Supplemental Oxygen at Baseline

Time: up to Day 28

Measure: Time from Randomization to Defervescence

Time: up to Day 28

Measure: Time from Randomization to Respiratory Rate ≤ 24 Breaths per Minute on Room Air

Time: up to Day 28

Measure: Time from Randomization to Cough Reported as Mild or Absent

Time: up to Day 28

Measure: Time from Randomization to Dyspnea Reported as Mild or Absent

Time: up to Day 28

Measure: Reduction of Immune Responses

Time: up to Day 28

Measure: Reduction in Viral Load

Time: up to Day 28

Measure: Duration of Hospitalization

Time: up to Day 28

Measure: Number of Fatalities

Time: up to Day 28

Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

Time: up to Day 28


Related HPO nodes (Using clinical trials)